Ritholtz Wealth Management Trims Stake in Regeneron Pharmaceuticals, Inc. $REGN

Ritholtz Wealth Management lowered its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 20.6% during the 2nd quarter, HoldingsChannel reports. The fund owned 386 shares of the biopharmaceutical company’s stock after selling 100 shares during the period. Ritholtz Wealth Management’s holdings in Regeneron Pharmaceuticals were worth $203,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in REGN. Brighton Jones LLC increased its stake in Regeneron Pharmaceuticals by 261.8% in the 4th quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company’s stock worth $675,000 after buying an additional 686 shares during the period. GAMMA Investing LLC increased its stake in Regeneron Pharmaceuticals by 41.8% in the 1st quarter. GAMMA Investing LLC now owns 1,286 shares of the biopharmaceutical company’s stock worth $816,000 after buying an additional 379 shares during the period. Blue Trust Inc. increased its stake in Regeneron Pharmaceuticals by 18.2% in the 1st quarter. Blue Trust Inc. now owns 331 shares of the biopharmaceutical company’s stock worth $210,000 after buying an additional 51 shares during the period. Oppenheimer & Co. Inc. increased its stake in Regeneron Pharmaceuticals by 8.2% in the 1st quarter. Oppenheimer & Co. Inc. now owns 18,143 shares of the biopharmaceutical company’s stock worth $11,507,000 after buying an additional 1,369 shares during the period. Finally, Oppenheimer Asset Management Inc. purchased a new position in Regeneron Pharmaceuticals in the 1st quarter worth about $1,246,000. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts recently commented on the stock. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $850.00 price target on shares of Regeneron Pharmaceuticals in a research note on Tuesday, October 14th. Truist Financial reduced their price target on shares of Regeneron Pharmaceuticals from $940.00 to $812.00 and set a “buy” rating on the stock in a research note on Monday, August 11th. Wells Fargo & Company downgraded shares of Regeneron Pharmaceuticals from an “overweight” rating to an “equal weight” rating and set a $580.00 price target on the stock. in a research note on Friday, August 1st. Raymond James Financial raised shares of Regeneron Pharmaceuticals to a “moderate buy” rating in a research report on Tuesday, September 2nd. Finally, Rothschild & Co Redburn assumed coverage on shares of Regeneron Pharmaceuticals in a research report on Thursday, August 14th. They set a “buy” rating and a $890.00 target price on the stock. Three research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Regeneron Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $817.88.

Regeneron Pharmaceuticals Trading Up 0.4%

NASDAQ REGN opened at $579.34 on Wednesday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.72 and a current ratio of 4.60. The company has a market capitalization of $61.40 billion, a price-to-earnings ratio of 14.60, a price-to-earnings-growth ratio of 1.80 and a beta of 0.31. The company’s 50-day simple moving average is $575.71 and its two-hundred day simple moving average is $562.26. Regeneron Pharmaceuticals, Inc. has a one year low of $476.49 and a one year high of $972.74.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 EPS for the quarter, beating analysts’ consensus estimates of $8.43 by $4.46. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The business had revenue of $3.68 billion for the quarter, compared to the consensus estimate of $3.30 billion. During the same quarter last year, the firm posted $11.56 EPS. The company’s revenue for the quarter was up 3.6% on a year-over-year basis. Equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Wednesday, September 3rd. Stockholders of record on Monday, August 18th were issued a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date was Monday, August 18th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is currently 8.87%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.